These results clearly showed that the expression level of NSFL1C/AURKB in prostate tumor samples from patients with BRCA2 deficiency was reduced, suggesting that the growth restriction phenotype as a result of SAC activation by BRCA2 deficiency may be relieved by the inhibition of NSFL1C/AURKB. This evidence concerns the gene AURKB and prostate neoplasm.